Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to stop Kids' eyes from getting worse during screen time

NCT ID NCT07390500

Disease control Sponsor: NovaSight Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

The DYMOND study is testing a digital app called TrackSight that may slow myopia (nearsightedness) in children aged 6 to 12. The app uses eye-tracking to keep central vision clear while slightly blurring the edges of the screen, based on principles that influence eye growth. About 150 kids in Israel and Hong Kong will use the app during normal screen time for 12 months to see if it safely slows the worsening of their eyesight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TrackSight digital medical application (device)
What this could lead to
If it works, this could offer a non-invasive, screen-based way to slow myopia progression in children, reducing the need for stronger glasses later.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not apply to all children. The effect may be small or not better than no treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 6-12 years -. Diagnosed with myopia: cycloplegic spherical or spherical equivalent (SER) between -0.75D and -5.00D, astigmatism ≤ -1.50D, anisometropia \< 1.50D * Visual acuity 20/32 or better (age-appropriate testing) in both eyes * Interocular VA difference ≤1.00 logMAR line * Subject in general good health and able, as per investigator decision, to comply with study visits and protocol procedures * The subject is using digital devices for at least 1 hour/day regularly according to parental report * Signed informed consent by legal parent/guardian and assent approval -. Currently wearing single vision refractive correction Exclusion Criteria: * Past or concurrent use of any other myopia treatment (e.g., atropine, orthokeratology, myopia control glasses/lenses) * Eye diseases or abnormality, developmental conditions, or past ocular surgeries or any other condition which could potentially affect refraction or AL progression according to the investigator's judgement * Current or prior history of manifest strabismus, amblyopia, or nystagmus * Subject cannot pass eye tracking calibration in at least 50% of cases, or cannot be tracked in at least 50% of the time during a screening eligibility test * Current or previous use of bifocal lenses, progressive-addition lenses, or multi-focal contact lenses * Premature gestational age ≤32 weeks or birth weight \<1500g.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kaplan MC

    RECRUITING

    Rehovot, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.